Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 73-80, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1010112
Responsible library:
WPRO
ABSTRACT
V-Raf murine sarcoma viral oncogene homolog B (BRAF) alteration is one of the most essential driver genes of non-small cell lung cancer (NSCLC). BRAF encodes serine/threonine protein kinases, and its mutations typically lead to protein compositional activation, thereby activating the mitogen-activated protein kinase kinase (MEK) signaling pathway. A promising new approach for the treatment of mutated BRAF and/or downstream MEK may provide customized treatment opportunities for BRAF driven NSCLC patients. However, combination therapy is necessary to overcome the difficulties such as short duration of benefit, poor therapeutic effect of non-V600 BRAF mutations and susceptibility to drug resistance. This article reviewed the progress in structural characteristics, related signaling pathways, mutation types of BRAF gene, and the clinical pathological relationship between BRAF mutations and NSCLC, as well as the therapy, in order to provide more evidences for clinical doctors to make treatment decisions.
.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Mitogen-Activated Protein Kinase Kinases
/
Proto-Oncogene Proteins B-raf
/
Protein Kinase Inhibitors
/
Lung Neoplasms
/
Mutation
Limits:
Animals
/
Humans
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2024
Type:
Article